Notes: June 7, 2019 -- Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, today reported that the previously announced business combination with Stellar Biotechnologies, Inc. (Nasdaq: SBOT) ("Stellar"), which was completed pursuant to a share exchange agreement, has closed. The combined company will focus on the development and advancement of innovative treatments for dermatological and gastrointestinal indications. The combined company will be called Edesa Biotech, Inc. and will commence trading on the Nasdaq Capital Market on June 10, 2019 under the symbol "EDSA." _________ April 27, 2019 -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in immunotherapy development pipelines, today is announcing a one-for-seven reverse share split of its common shares. The company anticipates that the reverse share split will become effective at 4:00 p.m. Eastern Time on May 4, 2018, and the company's common shares will trade on a post-split basis under the company's existing trading symbol "SBOT," at the market open on May 7, 2018. The new CUSIP number for the company's common shares will be 85855A302.